Walgreens names Mike Motz CEO as it transitions to private company
Sycamore’s Stefan Kaluzny said the deal gives Walgreens greater flexibility to move with “certainty, speed and focus” in serving millions of customers nationwide.
Walgreens Boots Alliance
End of an era: Walgreens exits S&P 500
The departure marks the end of Walgreens’ more than decade-long run in the S&P 500 index, reflecting its struggles to adapt to changing healthcare and retail markets.
Walgreens Clinical Trials celebrates three years
The initiative has proven the power of retail-based research in expanding access, according to Walgreens.
Walgreens to pay $350 million in U.S. opioid settlement
The settlement requires Walgreens to pay at least $300 million upfront, with an additional $50 million due if the company is sold, merged, or transferred before 2032.
Walgreens offering safe drug disposal on National Drug Take Back Day
National Prescription Drug Take Back Day is on Saturday, April 26.
WBA beats forecasts for Q2 sales and profits
“Second quarter results reflect disciplined cost management and improvement in U.S. health care."
Walgreens agrees to settle allegations of overbilling Medicaid programs
The settlement resolves, in part, claims brought by a whistleblower under the qui tam provisions of the federal, Massachusetts, and Georgia False Claims Acts.
WBA chair Pessina will almost double stake as part of Sycamore deal
Pessina will also deepen his involvement in the group ahead of a possible break-up, the FT said.
The implications of Sycamore Partners’ blockbuster acquisition of WBA
The acquisition aims to reinforce Walgreens, Boots and other consumer brands by leveraging WBA’s health care expertise and Sycamore’s strength in retail.
WBA has early settlement of certain prepaid variable share forward transactions
Following the early settlement, WBA now owns approximately 12.6 million shares of Cencora pledged under the remaining prepaid variable share forward contracts.